Roy Herbst | BiotechTV

top of page

ASCO 2026: Yale Cancer Center's Roy Herbst, recognized as one of the foremost leaders in lung and head & neck cancer research, shares his take on what's in focus at this year's ASCO Annual Meeting

He comments on the progress of PD-1 x VEGF, a closely watched RET inhibitor, and how the field is doing in head & neck cancer lately. Plus, the presentation that everyone is waiting for in pancreatic cancer.

Bright Minds

11 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

ASCO 2026: Yale Cancer Center's Roy Herbst, recognized as one of the foremost leaders in lung and head & neck cancer research, shares his take on what's in focus at this year's ASCO Annual Meeting

Follow BiotechTV

Sponsors

Sponsor Spotlight